<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489424</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446HUS136</org_study_id>
    <nct_id>NCT00489424</nct_id>
  </id_info>
  <brief_title>Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass</brief_title>
  <official_title>A Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study of Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an i.v. Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of acetaminophen or fluvastatin in reducing the rate of
      occurrence and the severity of post dose symptoms that may occur during the 3 day period
      following a zoledronic acid infusion in post menopausal women with low bone mass.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature or Use of Rescue Medication.</measure>
    <time_frame>0 - 3 days</time_frame>
    <description>Clinically significant increase in oral body temperature or used rescue medication ibuprofen &gt;= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature.</measure>
    <time_frame>0 - 3 days</time_frame>
    <description>Clinically significant increase in oral body temperature &gt;= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Used Rescue Medication.</measure>
    <time_frame>0 - 3 days</time_frame>
    <description>Patients that took rescue medication &gt;= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Rescue Medication Tablets Taken</measure>
    <time_frame>0 - 3 days</time_frame>
    <description>Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Rescue Medication After Infusion of Zoledronic Acid 5 mg.</measure>
    <time_frame>0 - 3 days</time_frame>
    <description>Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With a Major Increase (Worsening) in Severity of Questionnaire Symptoms.</measure>
    <time_frame>0 - 3 days</time_frame>
    <description>A major increase (worsening) in severity was defined as an increase in severity of 2 units or more from baseline at least once during the 3 days immediately following i.v. infusion of zoledronic acid 5 mg. The severity of the symptom was evaluated using a 4-point categorical scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Reporting Severe Questionnaire Symptoms.</measure>
    <time_frame>0 - 3 days</time_frame>
    <description>A severe questionnaire symptom was defined as experiencing a severe specified symptom (feeling feverish, experiencing headaches, having aches and pains of muscles and joints) at least once post-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Visual Analog Scale (VAS) Measurement of Symptom Severity</measure>
    <time_frame>0 - 3 days</time_frame>
    <description>Effect on severity of symptoms following i.v. infusion of zoledronic acid 5 mg. The VAS is a 100-mm linear visual analog scale (0 = no symptoms to 100 = severe symptoms). The baseline VAS measurement was defined as the VAS measurement recorded prior to the infusion.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">793</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <arm_group_label>Acetaminophen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvastatin</intervention_name>
    <arm_group_label>Fluvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Postmenopausal women greater than or equal to 45 and less than or equal to 79 years of
             age at randomization

          2. Women who are clinically indicated for treatment with Bisphosphonates for osteopenia
             or osteoporosis with a documented central (spine or hip) Bone Mineral Density T Score
             less than or equal to 1.5

        Exclusion Criteria:

          1. Any prior treatment with intravenous Bisphosphonates

          2. Oral treatment with Bisphosphonates for more than 8 weeks or within 6 months prior to
             the screening visit

          3. Patients who are taking, and are unwilling or unable to stop taking, certain
             medications

          4. Patients who require anticoagulant therapy

          5. Patients with a known hypersensitivity to ibuprofen, ACET, bisphosphonates, statins or
             with allergies manifested by attacks of asthma, urticaria or acute rhinitis following

          6. Proteinuria (protein detected on a urine dipstick) greater than or equal to 2+ at
             screening

          7. Protocol specific laboratory values that fall out of range for this study

          8. Ongoing infection (oral body temperature greater than or equal to 37.5C
             (99.5Â°F),chronic febrile disease or fever of unknown origin at screening or
             randomization

          9. Active dental infection, unhealed dental extraction or planned oral surgery within 3
             months after randomization

         10. History of iritis, uveitis or chronic conjunctivitis

         11. History of hypoparathyroidism, hyperparathyroidism or Paget's Disease

         12. Partial or total removal of parathyroid or thyroid gland

         13. History of malignancy of any organ system, treated or untreated, within the past 1
             year whether or not there is evidence of local recurrence or metastases, with the
             exception of localized basal cell carcinoma of the skin

         14. Treatment with an investigational drug within the previous 30 days of screening

         15. Patients with any medical or psychiatric condition which, in the opinion of the
             Principal Investigator, would preclude the participant from adhering to the protocol
             or completing the trial per protocol, or any patient who the Principal Investigator
             thinks should not participate in the study for any reason, including current drug or
             alcohol abuse

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Refer to the E-portal link for ZOL446HUS136</name>
      <address>
        <city>Http://www.osteoporosisclinicalresearch.com</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.osteoporosisclinicalresearch.com</url>
    <description>Click here for more information on this study</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <results_first_submitted>August 6, 2009</results_first_submitted>
  <results_first_submitted_qc>August 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2009</results_first_posted>
  <last_update_submitted>February 15, 2011</last_update_submitted>
  <last_update_submitted_qc>February 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>zoledronic acid</keyword>
  <keyword>post dose symptoms</keyword>
  <keyword>transient</keyword>
  <keyword>acetaminophen</keyword>
  <keyword>fluvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Fluvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
        </group>
        <group group_id="P2">
          <title>Acetaminophen</title>
          <description>2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
        </group>
        <group group_id="P3">
          <title>Fluvastatin</title>
          <description>2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="264"/>
                <participants group_id="P3" count="262"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="259"/>
                <participants group_id="P3" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
        </group>
        <group group_id="B2">
          <title>Acetaminophen</title>
          <description>2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
        </group>
        <group group_id="B3">
          <title>Fluvastatin</title>
          <description>2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="267"/>
            <count group_id="B2" value="264"/>
            <count group_id="B3" value="262"/>
            <count group_id="B4" value="793"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 45 and 55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 56 and 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="262"/>
                    <measurement group_id="B4" value="793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature or Use of Rescue Medication.</title>
        <description>Clinically significant increase in oral body temperature or used rescue medication ibuprofen &gt;= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.</description>
        <time_frame>0 - 3 days</time_frame>
        <population>Intent to Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen</title>
            <description>2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O3">
            <title>Fluvastatin</title>
            <description>2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature or Use of Rescue Medication.</title>
          <description>Clinically significant increase in oral body temperature or used rescue medication ibuprofen &gt;= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.</description>
          <population>Intent to Treat (ITT) population.</population>
          <units>proportion of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="264"/>
                <count group_id="O3" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increase in oral body temperature:Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.607"/>
                    <measurement group_id="O2" value="0.398"/>
                    <measurement group_id="O3" value="0.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase in oral body temperature:No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39"/>
                    <measurement group_id="O2" value="0.602"/>
                    <measurement group_id="O3" value="0.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature.</title>
        <description>Clinically significant increase in oral body temperature &gt;= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.</description>
        <time_frame>0 - 3 days</time_frame>
        <population>Intent to Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen</title>
            <description>2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O3">
            <title>Fluvastatin</title>
            <description>2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature.</title>
          <description>Clinically significant increase in oral body temperature &gt;= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. A clinically significant increase in body temperature was defined as an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius occurring at least once during the 3-day treatment period.</description>
          <population>Intent to Treat (ITT) population.</population>
          <units>proportion of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="264"/>
                <count group_id="O3" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increase in oral body temperature: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.105"/>
                    <measurement group_id="O2" value="0.049"/>
                    <measurement group_id="O3" value="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase in oral body temperature: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.891"/>
                    <measurement group_id="O2" value="0.951"/>
                    <measurement group_id="O3" value="0.885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Used Rescue Medication.</title>
        <description>Patients that took rescue medication &gt;= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.</description>
        <time_frame>0 - 3 days</time_frame>
        <population>Intent to Treat (ITT) population. One patient who used rescue medication in acetaminophen arm and two patients in fluvastatin arm were not included in analysis due to lack of documentation regarding use and exposure of rescue medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen</title>
            <description>2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O3">
            <title>Fluvastatin</title>
            <description>2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Used Rescue Medication.</title>
          <description>Patients that took rescue medication &gt;= 1 time during the 3-day period after i.v. infusion of zoledronic acid 5 mg. Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.</description>
          <population>Intent to Treat (ITT) population. One patient who used rescue medication in acetaminophen arm and two patients in fluvastatin arm were not included in analysis due to lack of documentation regarding use and exposure of rescue medication.</population>
          <units>proportion of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="264"/>
                <count group_id="O3" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Took rescue medication &gt;= 1 time: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.573"/>
                    <measurement group_id="O2" value="0.386"/>
                    <measurement group_id="O3" value="0.595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Took rescue medication &gt;= 1 time: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.423"/>
                    <measurement group_id="O2" value="0.614"/>
                    <measurement group_id="O3" value="0.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Rescue Medication Tablets Taken</title>
        <description>Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.</description>
        <time_frame>0 - 3 days</time_frame>
        <population>Number of patients who took rescue medication at least once. One patient in acetaminophen arm was not included in analysis since the number of tablets taken was not recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen</title>
            <description>2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O3">
            <title>Fluvastatin</title>
            <description>2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Rescue Medication Tablets Taken</title>
          <description>Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.</description>
          <population>Number of patients who took rescue medication at least once. One patient in acetaminophen arm was not included in analysis since the number of tablets taken was not recorded.</population>
          <units>tablets</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="4.41"/>
                    <measurement group_id="O2" value="5.7" spread="4.73"/>
                    <measurement group_id="O3" value="6.5" spread="4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Rescue Medication After Infusion of Zoledronic Acid 5 mg.</title>
        <description>Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.</description>
        <time_frame>0 - 3 days</time_frame>
        <population>Number of patients who took rescue medication at least once. Two patients who took rescue medication in fluvastatin arm were not included in analysis since the time rescue medication was taken was not recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen</title>
            <description>2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O3">
            <title>Fluvastatin</title>
            <description>2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Rescue Medication After Infusion of Zoledronic Acid 5 mg.</title>
          <description>Patients who experienced severe discomfort after their first home measurements and self-administration of study medication were allowed to take ibuprofen (200 mg tablets every 4-6 hours as needed) as rescue medication while continuing to take their study medication.</description>
          <population>Number of patients who took rescue medication at least once. Two patients who took rescue medication in fluvastatin arm were not included in analysis since the time rescue medication was taken was not recorded.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="12.21"/>
                    <measurement group_id="O2" value="28.2" spread="18.15"/>
                    <measurement group_id="O3" value="19.9" spread="40.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With a Major Increase (Worsening) in Severity of Questionnaire Symptoms.</title>
        <description>A major increase (worsening) in severity was defined as an increase in severity of 2 units or more from baseline at least once during the 3 days immediately following i.v. infusion of zoledronic acid 5 mg. The severity of the symptom was evaluated using a 4-point categorical scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).</description>
        <time_frame>0 - 3 days</time_frame>
        <population>Intent to Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen</title>
            <description>2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O3">
            <title>Fluvastatin</title>
            <description>2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With a Major Increase (Worsening) in Severity of Questionnaire Symptoms.</title>
          <description>A major increase (worsening) in severity was defined as an increase in severity of 2 units or more from baseline at least once during the 3 days immediately following i.v. infusion of zoledronic acid 5 mg. The severity of the symptom was evaluated using a 4-point categorical scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).</description>
          <population>Intent to Treat (ITT) population.</population>
          <units>proportion of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="264"/>
                <count group_id="O3" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feeling feverish</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.395"/>
                    <measurement group_id="O2" value="0.235"/>
                    <measurement group_id="O3" value="0.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.391"/>
                    <measurement group_id="O2" value="0.254"/>
                    <measurement group_id="O3" value="0.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aches and pains of muscles/joints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.477"/>
                    <measurement group_id="O2" value="0.337"/>
                    <measurement group_id="O3" value="0.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Reporting Severe Questionnaire Symptoms.</title>
        <description>A severe questionnaire symptom was defined as experiencing a severe specified symptom (feeling feverish, experiencing headaches, having aches and pains of muscles and joints) at least once post-baseline.</description>
        <time_frame>0 - 3 days</time_frame>
        <population>Intent to Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen</title>
            <description>2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O3">
            <title>Fluvastatin</title>
            <description>2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Reporting Severe Questionnaire Symptoms.</title>
          <description>A severe questionnaire symptom was defined as experiencing a severe specified symptom (feeling feverish, experiencing headaches, having aches and pains of muscles and joints) at least once post-baseline.</description>
          <population>Intent to Treat (ITT) population.</population>
          <units>proportion of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="264"/>
                <count group_id="O3" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feeling feverish</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.135"/>
                    <measurement group_id="O2" value="0.076"/>
                    <measurement group_id="O3" value="0.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.157"/>
                    <measurement group_id="O2" value="0.068"/>
                    <measurement group_id="O3" value="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aches and pains of muscles/joints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.303"/>
                    <measurement group_id="O2" value="0.212"/>
                    <measurement group_id="O3" value="0.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Visual Analog Scale (VAS) Measurement of Symptom Severity</title>
        <description>Effect on severity of symptoms following i.v. infusion of zoledronic acid 5 mg. The VAS is a 100-mm linear visual analog scale (0 = no symptoms to 100 = severe symptoms). The baseline VAS measurement was defined as the VAS measurement recorded prior to the infusion.</description>
        <time_frame>0 - 3 days</time_frame>
        <population>Intent to Treat (ITT) population. Number of participants analyzed may vary from ITT population due to some patients not reporting baseline or post baseline VAS measurement. Calculating change requires both baseline and post baseline values to be present.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen</title>
            <description>2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
          <group group_id="O3">
            <title>Fluvastatin</title>
            <description>2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Analog Scale (VAS) Measurement of Symptom Severity</title>
          <description>Effect on severity of symptoms following i.v. infusion of zoledronic acid 5 mg. The VAS is a 100-mm linear visual analog scale (0 = no symptoms to 100 = severe symptoms). The baseline VAS measurement was defined as the VAS measurement recorded prior to the infusion.</description>
          <population>Intent to Treat (ITT) population. Number of participants analyzed may vary from ITT population due to some patients not reporting baseline or post baseline VAS measurement. Calculating change requires both baseline and post baseline values to be present.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="264"/>
                <count group_id="O3" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to Day 1 - late evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="22.74"/>
                    <measurement group_id="O2" value="4.4" spread="18.00"/>
                    <measurement group_id="O3" value="6.0" spread="18.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Day 2 - late evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="25.86"/>
                    <measurement group_id="O2" value="11.8" spread="23.22"/>
                    <measurement group_id="O3" value="20.8" spread="27.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Day 3 - late evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="19.66"/>
                    <measurement group_id="O2" value="3.9" spread="17.59"/>
                    <measurement group_id="O3" value="6.6" spread="20.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At the end of study</time_frame>
      <desc>Safety Population</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
        </group>
        <group group_id="E2">
          <title>Acetaminophen</title>
          <description>2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
        </group>
        <group group_id="E3">
          <title>Fluvastatin</title>
          <description>2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.X</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="262"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.X</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="262"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

